RET fusion in advanced NSCLC was not discovered until 2012, and in early trials, multi-kinase inhibitors (MKIs) were primarily selected, which are other RTK and/or kinase inhibitors that inhibit RET-RTK drugs (such as VEGFR, BRAF, ALK, and EGFR, etc.)(Takahashi et al., 1985; Rocco et al., 2023). The gene discussed is ALK; the disease is non-small cell lung carcinoma.